Bleeding News and Research

RSS

Two new groups of viruses discovered within Bunyavirus family in Ivory Coast tropical forest

Researchers at the University of Bonn and the German Center for Infection Research (DZIF) have discovered two new groups of viruses within the Bunyavirus family in the tropical forest of Ivory Coast. Previously only five groups responsible for serious illnesses in humans and animals were known.

2 Jun 2015

Researchers develop hybrid tissue-engineered heart valve using patient's own cells

Researchers have created a new heart valve that combines a patient's own cells with metal alloy for a more durable replacement with potentially fewer complications, according to an article in the June 2015 issue of The Annals of Thoracic Surgery.

2 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.

30 May 2015

Study suggests race-specific equations to aid clinicians better calculate warfarin dosage

A new report demonstrates that clinical and genetic factors affecting dose requirements for warfarin vary by race. The study, published online today in Blood, the Journal of the American Society of Hematology, proposes race-specific equations to help clinicians better calculate warfarin dosage.

30 May 2015

Fair Rate Funding: Delaware woman gets $100M against Boston Scientific in TV mesh judgment

Fair Rate Funding, a leader in TV mesh lawsuit funding, reports that a state-court jury in Delaware found Thursday that Boston Scientific's Pinnacle and Advantage Fit inserts, designed to treat pelvic organ prolapse (POP) and Stress Urinary Incontinence (SUI) in women, were defectively designed and that company executives hid the design flaws from the plaintiff, Deborah Barba.

30 May 2015

Newer anticoagulant medication may increase risk of GI bleeding in older patients

In a study released online in April in the BMJ, a team of researchers from Mayo Clinic, and other collaborators, showed that for older patients, particularly individuals greater than 75 years of age, the risk of gastrointestinal (GI) bleeding is 3 to 5 times higher when taking newer anticoagulant medications dabigatran or rivaroxaban compared to when using warfarin.

30 May 2015

Rapid-deployment plasma protocol helps treat trauma victims faster in the ER

Traumatic injury is the leading cause of death among people under age 45, but if trauma physicians could deliver plasma to these injury victims within minutes of their arrival in the emergency room, more of them would stand a better chance of survival.

29 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

Carbon monoxide may actually protect the brain from damage after subarachnoid hemorrhage

Carbon monoxide is known by many as a poisonous gas that causes brain injury and other neurological symptoms, including memory loss and confusion. But a new study led by investigators at Beth Israel Deaconess Medical Center suggests the opposite may be true: When administered in small, carefully controlled amounts, carbon monoxide may actually protect the brain from damage following subarachnoid hemorrhage, a devastating stroke that results from bleeding in the brain.

27 May 2015

CSL Behring awarded NHF's 2015 Corporate Leadership Award

The National Hemophilia Foundation has awarded CSL Behring its 2015 Corporate Leadership Award as recognition for the company's longstanding and unwavering commitment to advancing science and improving the care of the bleeding disorders community. The award was accepted by Paul Perreault, CEO and Managing Director, CSL Limited, during the NHF Annual Spring Soiree in New York City on May 21.

24 May 2015

LSDF awards $2.9 million in funding to help commercialize major medical breakthroughs

Celiac disease-safe wheat, premature infant pain detection, and new medicines to fight flu and cancer are among the ideas to receive $2.9 million in funding from Washington's Life Sciences Discovery Fund (LSDF).

22 May 2015

Current menopausal hormone therapy users at increased risk of experiencing GI bleeding

Current users of menopausal hormone therapy (MHT) are more than twice as likely than non-users to develop lower gastrointestinal bleeding and ischemic colitis, especially if they use the therapy for longer durations, according to a study at Digestive Disease Week 2015.

19 May 2015

Blood-thinning treatment safe for patients with brain metastases

Cancer patients with brain metastases who develop blood clots may safely receive blood thinners without increased risk of dangerous bleeding, according to a study, published online today in Blood, the Journal of the American Society of Hematology.

19 May 2015

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

An early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung cancer has provided promising early results, prompting multiple phase III studies in lung cancer. The findings are being presented at the annual meeting of the American Society of Clinical Oncology.

15 May 2015

Automated analysis of vital signs could help prevent trauma patients from life-threatening bleeding

Automated analysis of the vital signs commonly monitored in patients being transported to trauma centers could significantly improve the ability to diagnose those with life-threatening bleeding before they arrive at the hospital, potentially saving their lives.

15 May 2015

Research finding could lead to better treatments for inflammatory bowel disease

Inflammatory bowel disease (IBD) afflicts 1.6 million people in the United States, causing abdominal pain, diarrhea, constipation, rectal bleeding and other potentially debilitating symptoms.

14 May 2015

MRI screening helps in accurate and rapid stroke treatment

Time is critical when it comes to stroke, and early treatment is associated with better outcomes. According to the Screening with MRI for Accurate and Rapid stroke Treatment (SMART) study, small changes in quality improvement procedures enabled clinicians to use MRI scans to diagnose stroke patients before giving acute treatment, within 60 minutes of hospital arrival.

14 May 2015

Comprehensive stroke centers reduce mortality risk in patients treated for hemorrhagic stroke

New research published today in the Journal of the American Heart Association indicates that patients who are treated for hemorrhagic stroke at a comprehensive stroke center are more likely to receive specialized treatment, reducing the risk of mortality.

7 May 2015

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to treatment and larger patient volumes due to more funding for critical care are anticipated to contribute to demand in emerging markets.

7 May 2015

Bleeding News and Research

Two new groups of viruses discovered within Bunyavirus family in Ivory Coast tropical forest

Researchers develop hybrid tissue-engineered heart valve using patient's own cells

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Study suggests race-specific equations to aid clinicians better calculate warfarin dosage

Fair Rate Funding: Delaware woman gets $100M against Boston Scientific in TV mesh judgment

Newer anticoagulant medication may increase risk of GI bleeding in older patients

Rapid-deployment plasma protocol helps treat trauma victims faster in the ER

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Carbon monoxide may actually protect the brain from damage after subarachnoid hemorrhage

CSL Behring awarded NHF's 2015 Corporate Leadership Award

LSDF awards $2.9 million in funding to help commercialize major medical breakthroughs

Current menopausal hormone therapy users at increased risk of experiencing GI bleeding

Blood-thinning treatment safe for patients with brain metastases

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

Automated analysis of vital signs could help prevent trauma patients from life-threatening bleeding

Research finding could lead to better treatments for inflammatory bowel disease

MRI screening helps in accurate and rapid stroke treatment

Comprehensive stroke centers reduce mortality risk in patients treated for hemorrhagic stroke

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News